Centivax key facts
as of Oct 2026- Developer of a broad-spectrum vaccine designed to treat and eradicate rapidly mutating pathogens.
- Centivax is valued at approximately $95.0M as of Oct 2026 (last reported valuation).
- It has raised $92.0M; the latest was Later Stage VC ($37.0M) in Mar 2026.
- Notable investors include NFX, Amplify Partners, Future Ventures (San Francisco), Patrick Collison, BOLD Capital Partners — 14 tracked in total.
- Status: Privately Held (backing).
Centivax's last reported valuation, Jul 2025. Nothing priced has surfaced since.
- ·The complete investor list: 14 names
- ·Watch Centivax: the Monday email on marks, rounds and moves
Centivax funding rounds
No funding rounds for Centivax are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Centivax
14+Centivax valuation
Centivax's last reported valuation was $95 million in Jul 2025. No priced round, secondary trade or fund mark has surfaced since.
Centivax investors
14 investors are on record for Centivax, including NFX, Amplify Partners, Future Ventures (San Francisco) and Patrick Collison. By type, the record holds 4 venture capital firms and 1 hedge fund.
About Centivax
Developer of a broad-spectrum vaccine designed to treat and eradicate rapidly mutating pathogens. The company utilizes computational immune engineering to develop therapeutic monoclonal antibodies against a variety of targets and builds a panel of neutralizing antibodies against severe acute respiratory syndrome coronavirus, enabling public health agencies, research institutions, and global healthcare systems to reduce outbreak risk and improve long term pandemic preparedness.
- Sector
- Healthcare
- HQ
- South San Francisco, CA, United States
- Founded
- 2019
- Employees
- 32
- Website
- centivax.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.